AsclepiX Therapeutics has secured $10 million in Series A-3 financing to advance the development of its lead clinical candidate, AXT107, for the treatment of neovascular retinal diseases, according to a press release.
The financing was led by Perceptive Advisors and joined by Hibiscus Capital Management Fund II, Rapha Capital Management and its managed fund, Rapha Capital PE Life Sciences Fund VI, as well as a new outside investor.
The funding will be put toward the execution of a phase 1/2a trial that will investigate AXT107 (gersizangitide) as a treatment for (Read more...)